Device maker Nemera announced that it has joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) as the consortium’s 9th associate member. Other companies that have joined as associate members in the past few years include Copley Scientific and Proveris Scientific.
Full membership in IPAC-RS is open to pharmaceutical companies that develop and manufacture orally inhaled and nasal drug products; associate membership is open to companies that make devices for OINDPs or offer services related to OINDP development and manufacturing.
IPAC-RS Chair Carla Vozone commented, “IPAC-RS welcomes Nemera as an associate member. In 2020, the IPAC-RS board of directors undertook a review of the IPAC-RS membership model. The board recognized that the OINDP industry continues to evolve and that IPAC-RS’ membership criteria should evolve with it. The board’s goal was to create a more inclusive IPAC-RS with greater engagement opportunities for a wider group of associate members. The revised Associate Membership category includes increased benefits and is intended to attract both large and smaller companies serving the OINDP industry. The board is confident that these changes will help expand the vibrant IPAC-RS OINDP community and enable more companies to engage in IPAC-RS. IPAC-RS appreciates the perspectives and commitment of associate members and looks forward to Nemera’s involvement.”
Nemera Global Category Manager Raphaële Audibert said, “Nemera is proud to announce that we are now part of IPAC-RS as an associate member. This membership is in line with our aim to be an active player in the inhalation scientific and regulatory community. We are delighted to be a part of IPAC-RS and look forward to fruitful collaboration within this organization.”
Scientific Director Simon Baconnier commented, “IPAC-RS plays an essential role in building consensus and contributing to the development of standards in regulatory science for orally inhaled and nasal drug products, launching and leading collaboration between the industry and global healthcare regulators. We are looking forward to actively contributing to the important work of IPAC-RS.”
Technology Product Manager Gildas Huet added, “Joining the IPAC-RS consortium is a great opportunity to share cross-industry understanding on a range of scientific and regulatory topics with a common objective of better serving patients.”
